Retatrutide in Type 2 Diabetes: What TRIUMPH-2 Found

Retatrutide in type 2 diabetes produced substantial average weight loss and improved HbA1c in the phase 3 TRIUMPH-2 trial. Among 1,152 adults with obesity or overweight and type 2 diabetes, once-weekly retatrutide was associated with average weight loss of 12.7% to 20.8% at 80 weeks on the study’s efficacy analysis, compared with 4.0% with placebo. Average HbA1c fell by about 1.4 to 1.6 percentage points with retatrutide, versus 0.2 points with placebo. Gastrointestinal adverse events were the most common safety findings.

Published September 29, 2026, TRIUMPH-2 provides phase 3 evidence in a population often underrepresented in obesity-drug studies: adults managing both excess weight and established type 2 diabetes. The detailed peer-reviewed report is available through the New England Journal of Medicine and its PubMed record.

The results need context. This was a placebo-controlled study, not a direct comparison with another approved medicine. It does not establish that retatrutide is approved, appropriate for every person, superior to another treatment, or proven to reduce cardiovascular or kidney events. Retatrutide remained investigational after this publication.

TRIUMPH-2 also addresses a different question from the related TRIUMPH-1 trial. Our TRIUMPH-1 coverage examined adults with obesity or overweight without type 2 diabetes. TRIUMPH-2 adds evidence from a separate population with different metabolic circumstances, outcomes, and safety data.

What TRIUMPH-2 studied

TRIUMPH-2 was a phase 3, randomized, double-blind, placebo-controlled trial. Randomization means participants were assigned to groups by chance. Double blinding means participants and investigators did not know the treatment assignments during the main study period. A placebo group gives researchers a comparison point for changes in weight, glucose measures, and adverse events.

The trial enrolled adults with obesity or overweight and type 2 diabetes. Screening occurred from July 11, 2023, through November 1, 2024. Of 2,047 people screened, 1,152 were randomized. There were 292 participants in the 4 mg retatrutide group, 284 in the 9 mg group, 287 in the 12 mg group, and 289 in the placebo group.

Participants had a mean age of 55.1 years. Women made up 48% of the trial population, and men made up 52%. Mean body-mass index at baseline was 38.2 kilograms per square meter. Mean baseline HbA1c was 7.71%. The reported median duration of obesity was 21 years, and the median duration of diabetes was 5.6 years.

The primary endpoint was percentage change in body weight from baseline to week 80 for the 9 mg and 12 mg groups compared with placebo. Weight change with 4 mg was a key secondary endpoint. Investigators also evaluated HbA1c, several cardiometabolic measures, adverse events, and discontinuation. These prespecified outcomes help distinguish the central trial questions from supportive or exploratory findings.

The study used once-weekly trial treatment. The doses and schedule described here are features of the published research protocol, not recommendations for use outside the study. Trial results describe group averages under controlled conditions; they do not determine an individual treatment plan.

How retatrutide is designed to work

Retatrutide is an investigational molecule designed to activate three hormone receptors: the glucose-dependent insulinotropic polypeptide receptor, usually called GIP; the glucagon-like peptide-1 receptor, or GLP-1 receptor; and the glucagon receptor. It is therefore described as a triple agonist.

GLP-1 receptor activity can increase glucose-dependent insulin secretion, affect appetite, slow stomach emptying, and influence food intake through gut-brain signaling. GIP is an incretin hormone that can also influence insulin secretion and energy regulation. Glucagon has a more complex metabolic role. It can raise blood glucose in some settings, while glucagon receptor activity may also affect energy expenditure, liver fat, and lipid metabolism.

The rationale for triple receptor activity is not that activating more pathways automatically creates a better medicine. Each pathway may contribute different effects, and the balance between them matters. Researchers must assess whether a compound can improve weight and glucose measures while maintaining an acceptable safety and tolerability profile.

That is one reason phase 3 trials matter. Earlier research can provide a biological rationale and initial signals. A larger late-stage trial tests whether those signals remain meaningful in a broader population over a longer period. TRIUMPH-2 does not settle every question about triple agonism, but it provides much stronger evidence than early studies alone.

Retatrutide in type 2 diabetes: weight results at 80 weeks

The main result was dose-related average weight loss. On the efficacy estimand, average weight change at week 80 was 12.7% with retatrutide 4 mg, 19.1% with 9 mg, and 20.8% with 12 mg. The placebo group had an average weight change of 4.0%. These outcomes are reported in the peer-reviewed TRIUMPH-2 publication.

The study also reported a treatment-regimen estimand. This analysis includes all randomized participants and is more affected by discontinuation, rescue therapy, and missing data. Under this approach, average weight change was approximately 11.9% with 4 mg, 16.8% with 9 mg, and 18.8% with 12 mg, compared with 5.1% with placebo.

Neither approach should be read as a universal prediction. The efficacy estimand estimates outcomes under continued assigned treatment without prohibited rescue therapy. The treatment-regimen estimand asks a broader assignment-based question that includes participants who stopped treatment or required other interventions. Both are useful, but they answer different questions.

This distinction matters when weight-loss results are compared across headlines or studies. A percentage may look precise, but its meaning depends on the population, follow-up length, analysis method, discontinuation patterns, and endpoint definition. Readers should check whether a report describes an efficacy analysis or a treatment-regimen analysis before making cross-study comparisons.

The study average also does not describe every participant’s experience. Some people may have lost more weight than the mean, some less, and some may have stopped treatment. A randomized trial can estimate average effects in its study population, but it cannot predict the outcome for a specific person.

What happened to HbA1c?

HbA1c is a laboratory marker that reflects average glucose exposure over roughly the previous two to three months. It is widely used in type 2 diabetes research because it gives a longer-term view than a single glucose measurement. Mean HbA1c at the start of TRIUMPH-2 was 7.71%.

At week 80, HbA1c fell by about 1.4 percentage points in the 4 mg group, 1.6 points in the 9 mg group, and 1.5 points in the 12 mg group. The placebo group had an average reduction of about 0.2 points. These results show that the observed effects were not limited to body weight in this study population.

The publication also reported that 73.1% of participants in the 4 mg group, 79.2% in the 9 mg group, and 79.0% in the 12 mg group reached an HbA1c of 6.5% or lower. In the placebo group, 26.3% reached that threshold. About 40.0% of the 9 mg group and 39.3% of the 12 mg group reached an HbA1c below 5.7%.

Threshold findings need careful interpretation. Reaching a laboratory threshold during a trial does not prove that diabetes has been permanently reversed. The HbA1c-below-5.7% analysis was not controlled for all possible multiple comparisons. It is best understood as a reported secondary result, not the central proof of the trial.

It is also important not to turn group findings into individualized advice. Participants entered the study with different disease histories, body sizes, background care, and responses to treatment. TRIUMPH-2 reports what happened on average within the trial. It does not identify one result, dose, or target that is suitable for all people with type 2 diabetes.

Other metabolic changes reported

Weight and HbA1c were the most prominent results, but the study also reported changes in cardiometabolic measures. At 12 mg, investigators reported reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and high-sensitivity C-reactive protein.

These findings are relevant because obesity and type 2 diabetes often occur alongside elevated triglycerides, blood-pressure changes, insulin resistance, and chronic low-grade inflammation. A lower value in one of these measures can be scientifically informative. However, improvement in a biomarker is not the same as evidence of fewer heart attacks, strokes, kidney failure events, or deaths.

TRIUMPH-2 was not designed as a cardiovascular-outcomes trial. These changes alone cannot establish cardiovascular or kidney protection. Trials designed around clinical events generally need more participants and longer follow-up. This distinction matters because metabolic biomarkers may support a hypothesis without showing whether a treatment changes major long-term outcomes.

The 80-week duration is longer than many early studies and gives researchers more time to observe weight trajectories, glucose measures, and tolerability. Even so, it is not lifelong evidence. Questions about maintenance, weight change after treatment stops, body composition, rare adverse events, and outcomes over several years remain outside the scope of this report.

Safety and treatment discontinuation

The safety profile was broadly consistent with gastrointestinal effects often reported with incretin-based therapies. Diarrhea, nausea, constipation, and vomiting were among the most frequent adverse events. Appetite reduction was also reported. Events were generally described as mild or moderate, though individual experiences can differ.

Discontinuation because of adverse events occurred in 3.8% of participants receiving 4 mg, 11.6% receiving 9 mg, and 7.7% receiving 12 mg. The placebo discontinuation rate was 4.9%. These figures matter because efficacy results should be considered alongside tolerability and the proportion of participants able to remain on assigned treatment.

The discontinuation rate was highest in the 9 mg group rather than the 12 mg group. That observation does not establish that 9 mg is less tolerable overall. Discontinuations can reflect dose escalation, timing, participant characteristics, reporting patterns, and chance. The more limited conclusion is that the relationship between studied dose and tolerability was not a simple straight line in this trial.

Continued safety monitoring remains important for an investigational triple agonist. Glucagon receptor activity may affect heart rate, blood pressure, liver metabolism, and energy expenditure. A phase 3 study can identify common patterns during its follow-up period, but it is not large or long enough to resolve every possible rare or long-term safety question.

For that reason, the safety findings should be read carefully. TRIUMPH-2 provides useful information about adverse events and discontinuations over 80 weeks. It does not establish the full long-term safety profile of retatrutide, nor does it prove that a trial formulation is equivalent to any product outside regulated clinical development.

Why the diabetes population matters

TRIUMPH-2 should not be treated as interchangeable with an obesity-only trial. It enrolled adults with obesity or overweight and type 2 diabetes, while TRIUMPH-1 enrolled adults with obesity or overweight without type 2 diabetes. Diabetes can affect glucose metabolism, background medication use, baseline characteristics, and the way weight changes during treatment.

People with type 2 diabetes may lose less weight than people without diabetes in some obesity trials. Differences in insulin resistance, disease duration, background therapy, body composition, and glucose management may all contribute. That means a 20.8% result in TRIUMPH-2 should not be placed on a single leaderboard beside an obesity-only result without explaining the population and analysis method.

The comparison is useful only when it remains descriptive. Both studies help characterize retatrutide’s phase 3 program, but they do not create a direct head-to-head test between people with and without diabetes. Differences between separate trials may arise from more than the presence or absence of diabetes.

TRIUMPH-2’s most important contribution is therefore not simply another large percentage. It shows that the triple-receptor approach produced simultaneous average changes in body weight and HbA1c in a large population with established type 2 diabetes. This is a meaningful addition to the evidence base, while comparative and long-term questions remain open.

How TRIUMPH-2 fits the retatrutide evidence base

Retatrutide first drew attention through earlier obesity research in adults without diabetes. The phase 3 program expanded the evidence to clinically distinct groups. TRIUMPH-1 addressed obesity without type 2 diabetes. TRIUMPH-2 addressed obesity or overweight with type 2 diabetes.

TRIUMPH-2 does not show that retatrutide is superior to <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide or tirzepatide. Its comparator was placebo, not another approved incretin-based medicine. Indirect comparisons between separate studies are unreliable because populations, follow-up periods, background treatments, endpoints, and statistical analyses can differ.

The broader research field also includes medicines at very different stages of development. For example, our review of the ribupatide first-in-human trial describes an early study in healthy adults. That work and TRIUMPH-2 should not be ranked as though they provide the same type of evidence. A small early pharmacology study and a large phase 3 trial answer different questions.

Phase 3 evidence is especially valuable because it tests efficacy and tolerability in many more people over a longer period. Yet even a positive phase 3 study has limits. It does not automatically answer how a treatment compares with established therapies, how results persist over many years, or whether biomarker improvements translate into fewer clinical events.

What TRIUMPH-2 does not prove

• It does not prove that retatrutide is approved or available as a standard treatment.
• It does not show that a product outside regulated development programs matches the studied formulation.
• It does not establish cardiovascular or kidney protection.
• It does not prove that every participant will lose 20.8% of body weight.
• It does not establish that any studied dose is appropriate for every person.
• It does not establish durable weight maintenance after treatment stops.
• It does not provide a head-to-head comparison with semaglutide or tirzepatide.

These limits are not reasons to dismiss the findings. They define the boundaries of what the study can support. The trial provides substantial evidence for average weight and HbA1c changes over 80 weeks in its enrolled population. It does not provide evidence for claims that require a different design, longer observation, or direct comparison.

The study was funded by the compound’s developer, and several authors were affiliated with the sponsor. That arrangement is common in late-stage pharmaceutical research. It also makes transparent methods, peer review, access to the full report, and continued scientific scrutiny important. The peer-reviewed report is stronger evidence than a press release alone, but sponsor-funded research still warrants normal critical attention.

What comes next for retatrutide research

The next major questions concern durability, safety, and comparison. Researchers will need to assess whether changes in weight and HbA1c persist beyond 80 weeks and what happens after treatment interruption. Body-composition questions, including preservation of functional lean tissue, also remain important.

Cardiovascular and kidney outcomes will require dedicated research. Lower weight, blood pressure, triglycerides, or inflammatory markers can support a biological rationale, but outcome trials are needed to measure actual events. Such studies usually require more participants and longer follow-up than a weight-loss efficacy trial.

Direct comparative research is another gap. Retatrutide will need to be evaluated alongside approved GLP-1 and GIP/GLP-1 therapies in comparable populations using similar follow-up periods and endpoint definitions. Without that design, cross-trial comparisons can overstate or understate possible differences.

For now, TRIUMPH-2 is best viewed as a significant phase 3 evidence update rather than a final answer. It strengthens the case for continued study of triple GIP, GLP-1, and glucagon receptor agonism in metabolic disease while identifying questions that still require separate research.

Bottom line

TRIUMPH-2 is an important phase 3 study of retatrutide in adults with obesity or overweight and type 2 diabetes. At 80 weeks, the 12 mg group had an average 20.8% body-weight reduction on the efficacy analysis and an average HbA1c reduction of about 1.5 percentage points. Gastrointestinal adverse events were common, and discontinuation because of adverse events was a meaningful part of the results.

The findings support continued research into triple GIP, GLP-1, and glucagon receptor agonism. They do not establish approval, long-term cardiovascular benefit, a direct advantage over other medicines, or a result that can be predicted for every individual. The most accurate conclusion is that TRIUMPH-2 provides substantial phase 3 efficacy evidence while leaving important questions about comparative effectiveness, durability, rare safety events, and clinical outcomes unanswered.

Frequently asked questions

What did the TRIUMPH-2 trial study?

TRIUMPH-2 was a randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide in 1,152 adults with obesity or overweight and type 2 diabetes. Participants received 4 mg, 9 mg, 12 mg, or placebo for 80 weeks.

How much weight did retatrutide produce in TRIUMPH-2?

On the trial’s efficacy analysis, average weight loss at week 80 was 12.7% with 4 mg, 19.1% with 9 mg, and 20.8% with 12 mg, compared with 4.0% with placebo. The treatment-regimen analysis, which counted all randomized participants, produced smaller estimates.

How did retatrutide affect HbA1c?

HbA1c started at an average of about 7.7%. At week 80, it fell by about 1.4 percentage points with 4 mg, 1.6 points with 9 mg, and 1.5 points with 12 mg, compared with 0.2 points with placebo.

Was retatrutide approved after TRIUMPH-2?

No. Retatrutide remained investigational after the September 29, 2026 publication. TRIUMPH-2 provides clinical trial evidence, but it is not an approval decision or prescribing recommendation.

What were the main safety findings?

Gastrointestinal adverse events, including diarrhea, nausea, constipation, and vomiting, were the most common findings. Treatment discontinuation because of adverse events ranged from 3.8% to 11.6% across retatrutide groups, compared with 4.9% with placebo. Longer-term follow-up remains important.